Articles Archives - Page 132 of 714

MondayOct 02, 2023 11:15 am

Meeting Phase 2 KPIs, Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) Emerging as a Model for Sustainable Growth in the Oil & Gas Industry

Prospera in 2021 launched a new strategy to improve margins and oil and gas production while minimizing environmental impact Horizontal well-technology allows for increase in production and Prospera has now abandoned 60 vertical wells as part of its three-year LMRP to reclaim surface land and reduce environmental footprint that will see 200+ vertical wells abandoned Prospera this month completed the drilling of four horizontal wells of a ten-well multi-pad infill drill program that can add an additional ~750 bpd at a low decline to Prospera’s current 900+boepd With more than 42,000 cumulative acres across Cuthbert, Luseland and Heart Hills in…

MondayOct 02, 2023 10:30 am

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) Looks to Secure Property Rights at Zigzag Lithium Project Site; Announces Start of Drill Work at Ruby Graphite Mine

With EV sales skyrocketing around the world, securing lithium and natural graphite supplies has become a priority for battery manufacturers Reflex Advanced Materials has centered its efforts around catering to the lithium and graphite supply chains, with the company announcing that it had fulfilled the penultimate capital payment step needed to secure 100% ownership of its Ontario-based Zigzag lithium project The company also took the opportunity to announce the start of core exploratory drill work within the Montana-based Ruby Graphite project As auto sales staged a significant recovery in the United Kingdom this summer, electric vehicles led the surge. The…

MondayOct 02, 2023 9:45 am

SenesTech Inc. (NASDAQ: SNES) to Deploy ContraPest Solutions for Wastewater Facilities in Washington and California

SenesTech, with its proprietary biological solution for efficiently and safely reducing rat populations without killing, represents a remarkable new path to clean cities, businesses, and households According to pest industry figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States ContraPest offers a unique solution for wastewater facilities because it is non-poisonous and comes in a variety of formats that can help control rat populations where other approaches fall short SenesTech (NASDAQ: SNES), the rodent fertility control experts and the inventor of the only EPA-registered contraceptive for male and female rats, recently…

MondayOct 02, 2023 9:00 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Finalizes Rebrand to Reflect New Strategic Direction, Diversification

Scinai Immunotherapeutics, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, recently finalized a major rebrand, changing its corporate name from BiondVax Pharmaceuticals The rebrand is part of a series of steps to better reflect the company’s new direction and new developments aimed at new scientific breakthroughs Amir Reichman took over as CEO in March 2021 and together with the Board of Directors, began implementing a raft of changes aimed at redirecting the company’s focus and diversifying corporate risks Scinai is developing a pipeline of novel NanoAbs, with its development pipeline including NanoAbs for the treatment of…

FridaySep 29, 2023 11:15 am

PaxMedica Inc. (NASDAQ: PXMD) Releases Compelling Video: Progress Report on ASD and Hope for the Future

Autism Spectrum Disorder (“ASD”) has seen a staggering fourfold increase in the United States over the past two decades PaxMedica proudly stands as the sole publicly traded U.S. company singularly dedicated to addressing the challenges posed by Autism Our pioneering lead product, PAX-101, has shown significant promise in alleviating core Autism symptoms during early trials In 2024, we're poised to submit a New Drug Application (“NDA”) for PAX-101 to treat Human African Trypanosomiasis (“HAT”), a rare disease also known as African Sleeping Sickness, as part of the Neglected Rare Tropical Disease Program With NDA approval, we anticipate the potential to…

FridaySep 29, 2023 10:30 am

GEMXX Corp. (GEMZ) Plans 300% YoY Expansion in Gemstone and Jewelry Production to Meet Growing Demand

GEMXX is a mine-to-market enterprise that specializes in the production and distribution of gemstones, like Ammolite, and jewelry on a global scale Ammolite is a rare gemstone that exhibits a unique iridescence and is only found in southern Alberta, Canada The company recently announced that demand for its Ammolite in jewelry designs by Kenneth Bradley is growing exponentially GEMXX plans to expand gemstone and jewelry production by 300% year over year in response to growing demand Its shopping channel division is preparing to supply $5.5 million worth of Ammolite gemstones and jewelry over the next 12 months Although officially recognized…

FridaySep 29, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Advancing its DehydraTECH(TM) Technology, Having Demonstrated its Potential Across Multiple Areas of Application

Lexaria’s patented DehydraTECH(TM)-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks This technology has also shown positive impacts in obese diabetic-conditioned animals from its DIAB-A22-1 pre-clinical study The NIC-H22-1 human nicotine study also demonstrated a statistically significant difference to achieve maximum blood saturation These results have demonstrated DehydraTECH’s potential while propping it to take advantage of vastly untapped markets with potential for growth in the coming years Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for its growing range of applications, which include oral…

FridaySep 29, 2023 9:00 am

Unveiling the Neuroprotective Power of CNMAu8 A Promising Breakthrough in Neurodegenerative Disease Treatment

by Elaine Mendonça On September 28, 2023, Clene Inc. (NASDAQ: CLNN) made an exciting announcement regarding their groundbreaking research on the investigational drug CNM-Au8. In a scientific paper published in the esteemed journal Small, Clene Inc. revealed the catalytic mechanism of action behind the therapeutic properties of CNM-Au8. The study showcased the remarkable neuroprotective abilities of CNM-Au8, attributing its success to its unique catalytic activity. When exposed to toxins that typically lead to neuronal death, CNM-Au8 treatment exhibited a remarkable ability to promote cell survival and preserve the intricate network of neurites. To truly understand the underlying mechanisms responsible for CNM-Au8’s neuroprotective function,…

ThursdaySep 28, 2023 10:30 am

Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) Strategically Positioned for Record Growth Amidst Canada’s Push for Sustainability in the Oil and Gas Industry

As one of the oil and gas leaders, Canada is the third-largest holder of proven oil reserves in the world; the country’s oil and gas sector is not only big but also green, positioning Canada as an energy powerhouse with an eye on a greener future The sector reported output growth while slashing emissions, standing as a testament that achieving both growth and environmental sustainability is possible Amid Canada's firm commitment to a greener future, companies like Prospera Energy are set to benefit as the country seizes the opportunity of the burgeoning market while still ensuring sustainability Prospera Energy (TSX.V:…

ThursdaySep 28, 2023 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Presents Achievements, Goals at H.C. Wainwright 25th Annual Global Investment Conference in New York City

RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during the conference The company's primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults The global medical aesthetics market was estimated at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027, growing at a CAGR of 11% RVL Pharmaceuticals markets UPNEEQ(R) to HCPs and plans to launch a direct-to-consumer campaign later this year RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization and development of products…

Site Search

Company Search

Category: Articles